Encouraging next step in Alzheimer’s research

Alzheimer; News from the web:

AstraZeneca plc (AZNAnalyst Report) and Eli Lilly and Company (LLYAnalyst Report) announced that a phase II/III study (AMARANTH) on their BACE inhibitor, AZD3293, will continue into phase III of the phase II/III seamless study. AZD3293 is being evaluated for the treatment of patients suffering from early Alzheimer’s disease – the most common form of dementia.

Read all about it HERE